Non-Interventional Study on Edoxaban Treatment in Routine Clinical Practice for Patients With Non Valvular Atrial Fibrillation
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 16 May 2018
At a glance
- Drugs Edoxaban (Primary)
- Indications Atrial fibrillation
- Focus Adverse reactions
- Acronyms ETNA-AF-Europe
- Sponsors Daiichi Sankyo Company; Daiichi Sankyo Inc
- 20 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 11 Oct 2017 Planned End Date changed from 1 Jan 2023 to 1 Apr 2023.
- 11 Oct 2017 Planned primary completion date changed from 1 Jan 2022 to 1 Apr 2022.